TY  - JOUR
AU  - Habl, Gregor
AU  - Uhl, Matthias
AU  - Katayama, Sonja
AU  - Kessel, Kerstin A
AU  - Hatiboglu, Gencay
AU  - Hadaschik, Boris
AU  - Edler, Lutz
AU  - Tichy, Diana
AU  - Ellerbrock, Malte
AU  - Haberer, Thomas
AU  - Wolf, Maja B
AU  - Schlemmer, Heinz-Peter
AU  - Debus, Jürgen
AU  - Herfarth, Klaus
TI  - Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study-The IPI Trial.
JO  - International journal of radiation oncology, biology, physics
VL  - 95
IS  - 1
SN  - 0360-3016
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2017-02065
SP  - 435 - 443
PY  - 2016
AB  - The purpose of this study was to compare safety and feasibility of proton therapy with that of carbon ion therapy in hypofractionated raster-scanned irradiation of the prostate, in a prospective randomized phase 2 trial.In this trial, 92 patients with localized prostate cancer were enrolled. Patients were randomized to receive either proton therapy (arm A) or carbon ion therapy (arm B) and treated with a total dose of 66 Gy(relative biological effectiveness [RBE]) administered in 20 fractions (single dose of 3.3 Gy[RBE]). Patients were stratified by the use of antihormone therapy. Primary endpoint was the combined assessment of safety and feasibility. Secondary endpoints were specific toxicities, prostate-specific antigen progression-free survival (PFS), overall survival (OS), and quality of life (QoL).Ninety-one patients completed therapy and have had a median follow-up of 22.3 months. Among acute genitourinary toxicities, grade 1 cystitis rates were 34.1
KW  - Androgen Antagonists (NLM Chemicals)
KW  - Prostate-Specific Antigen (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:27084659
DO  - DOI:10.1016/j.ijrobp.2016.02.025
UR  - https://inrepo02.dkfz.de/record/125941
ER  -